POAI
Predictive Oncology Inc.NASDAQHealthcare$4.10+15.17%ClosedMarket Cap: $3.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.55
P/S
115.12
EV/EBITDA
-0.02
DCF Value
$0.84
FCF Yield
-65.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
42.0%
Operating Margin
-185860.6%
Net Margin
-186053.4%
ROE
2959.0%
ROA
-440.7%
ROIC
-472.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $8.7K | 89.3% | $-224.6M | $-150.9M | $122.73 | — |
| FY 2025 | $125.3K | 42.0% | $-232.9M | $-233.1M | $-13.37 | — |
| Q3 2025 | $3.6K | -131.0% | $-3.3M | $-77.7M | $-107.25 | — |
| Q2 2025 | $2.7K | -579.4% | $-2.7M | $-2.1M | $-0.23 | — |
| Q1 2025 | $110.3K | 59.1% | $-2.3M | $-2.4M | $-0.34 | — |
| Q4 2024 | $611.6K | 52.5% | $-2.1M | $-2.2M | $-0.40 | — |
| FY 2024 | $1.6M | 49.1% | $-10.9M | $-12.2M | $-2.24 | — |
| Q3 2024 | $345.7K | 43.0% | $-2.3M | $-3.1M | $-0.48 | — |
| Q2 2024 | $278.7K | 45.1% | $-3.2M | $-3.2M | $-0.68 | — |
| Q1 2024 | $419.6K | 16.6% | $-4.2M | $-4.2M | $-1.04 | — |
| Q4 2023 | $335.0K | -21.3% | $-3.5M | $-3.5M | $-0.86 | — |
| FY 2023 | $1.6M | 62.6% | $-12.1M | $-14.0M | $-3.48 | — |